Nuvectis Pharma (NVCT) Competitors $10.96 +0.55 (+5.28%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NVCT vs. MLYS, ETNB, COLL, DYN, ELVN, RCUS, CMRX, CDMO, SYRE, and NTLAShould you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Mineralys Therapeutics (MLYS), 89bio (ETNB), Collegium Pharmaceutical (COLL), Dyne Therapeutics (DYN), Enliven Therapeutics (ELVN), Arcus Biosciences (RCUS), Chimerix (CMRX), Avid Bioservices (CDMO), Spyre Therapeutics (SYRE), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Nuvectis Pharma vs. Mineralys Therapeutics 89bio Collegium Pharmaceutical Dyne Therapeutics Enliven Therapeutics Arcus Biosciences Chimerix Avid Bioservices Spyre Therapeutics Intellia Therapeutics Mineralys Therapeutics (NASDAQ:MLYS) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership. Do insiders & institutionals believe in MLYS or NVCT? 84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 33.2% of Mineralys Therapeutics shares are owned by insiders. Comparatively, 35.8% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings and valuation, MLYS or NVCT? Nuvectis Pharma is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMineralys TherapeuticsN/AN/A-$177.81M-$3.64-3.80Nuvectis PharmaN/AN/A-$22.26M-$1.11-9.62 Does the MarketBeat Community favor MLYS or NVCT? Mineralys Therapeutics received 7 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. Likewise, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 92.31% of users gave Nuvectis Pharma an outperform vote. CompanyUnderperformOutperformMineralys TherapeuticsOutperform Votes19100.00% Underperform VotesNo VotesNuvectis PharmaOutperform Votes1292.31% Underperform Votes17.69% Does the media refer more to MLYS or NVCT? In the previous week, Mineralys Therapeutics had 8 more articles in the media than Nuvectis Pharma. MarketBeat recorded 8 mentions for Mineralys Therapeutics and 0 mentions for Nuvectis Pharma. Mineralys Therapeutics' average media sentiment score of 1.54 beat Nuvectis Pharma's score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Mineralys Therapeutics Very Positive Nuvectis Pharma Neutral Which has more risk and volatility, MLYS or NVCT? Mineralys Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Is MLYS or NVCT more profitable? Mineralys Therapeutics' return on equity of -67.97% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Mineralys TherapeuticsN/A -67.97% -62.40% Nuvectis Pharma N/A -155.80%-104.02% Do analysts recommend MLYS or NVCT? Mineralys Therapeutics presently has a consensus price target of $33.00, suggesting a potential upside of 138.44%. Nuvectis Pharma has a consensus price target of $15.67, suggesting a potential upside of 46.76%. Given Mineralys Therapeutics' higher possible upside, analysts plainly believe Mineralys Therapeutics is more favorable than Nuvectis Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mineralys Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryMineralys Therapeutics beats Nuvectis Pharma on 8 of the 13 factors compared between the two stocks. Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCT vs. The Competition Export to ExcelMetricNuvectis PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$249.71M$6.57B$5.40B$7.68BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-9.207.0922.2118.29Price / SalesN/A263.59392.81105.26Price / CashN/A65.6738.2034.62Price / Book15.256.396.774.22Net Income-$22.26M$142.49M$3.21B$247.51M7 Day Performance20.49%7.35%4.84%5.54%1 Month Performance8.82%-8.25%-6.33%-4.23%1 Year Performance59.09%-1.81%16.11%4.29% Nuvectis Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCTNuvectis Pharma2.0218 of 5 stars$10.96+5.3%$15.67+42.9%+58.0%$256.38MN/A-9.458Positive NewsGap UpHigh Trading VolumeMLYSMineralys Therapeutics2.6647 of 5 stars$13.92+3.9%$33.00+137.1%+18.4%$873.97MN/A-3.8228Positive NewsGap UpETNB89bio2.9288 of 5 stars$5.92+7.1%$27.56+365.5%-25.8%$864.23MN/A-2.0340Options VolumeNews CoverageCOLLCollegium Pharmaceutical4.0946 of 5 stars$26.73+1.6%$43.60+63.1%-27.7%$858.89M$631.45M11.52210DYNDyne Therapeutics3.5547 of 5 stars$7.47+6.1%$47.46+535.4%-57.6%$845.01MN/A-2.10100Upcoming EarningsNews CoverageELVNEnliven Therapeutics1.9745 of 5 stars$17.19+4.1%$40.33+134.6%+2.3%$842.38MN/A-9.0550News CoverageRCUSArcus Biosciences2.3056 of 5 stars$7.67-6.2%$30.25+294.4%-47.6%$806.41M$258M-2.43500Analyst ForecastCMRXChimerix2.7795 of 5 stars$8.54+0.2%$8.53-0.1%N/A$801.09M$212,000.00-9.0990Upcoming EarningsAnalyst ForecastCDMOAvid Bioservices0.7195 of 5 stars$12.50+0.1%$12.25-2.0%+87.1%$799.18M$139.91M-5.23320High Trading VolumeSYRESpyre Therapeutics1.9831 of 5 stars$13.02+6.5%$49.57+280.7%-58.5%$784.55M$890,000.00-1.74100Positive NewsNTLAIntellia Therapeutics4.534 of 5 stars$7.50+1.2%$37.56+400.7%-62.4%$776.38M$57.88M-1.38600Analyst Upgrade Related Companies and Tools Related Companies MLYS Alternatives ETNB Alternatives COLL Alternatives DYN Alternatives ELVN Alternatives RCUS Alternatives CMRX Alternatives CDMO Alternatives SYRE Alternatives NTLA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVCT) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NVCT Stock Free NVCT Stock Alerts